<DOC>
	<DOCNO>NCT01931046</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness AD5-SGE-REIC/Dkk-3 subject localized prostate cancer .</brief_summary>
	<brief_title>Study Recombinant Adenovirus Treat Localized Prostate Cancer</brief_title>
	<detailed_description>This phase 1/2a clinical trial subject diagnose prostate cancer evaluate effectiveness Ad5-SGE-REIC/Dkk-3 treatment localized prostate cancer . Subjects enrol diagnosed localized prostate cancer ( clinical stage T1/T2 ) Gleason score 6 7 ( 3+4 4+3 ) . Subjects receive four ( 4 ) transrectal ultrasound ( TRUS ) -guided IT treatments Ad5-SGE-REIC/Dkk-3 prostate approximately 6-weeks apart . Each treatment cycle perform use minimum three track injection prostrate use total 3 mL volume . Approximately 2 mL total volume inject dense area cancer base biopsy MRI mapping ( fusion biopsy ) 1 mL total volume inject opposite lobe prostate area ensure complete saturation prostate multiple injection . Subjects , opinion investigator , progress time second injection Ad5-SGE-REIC/Dkk-3 may discontinue treat accord standard medical practice .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Key 1 . Male age 50 80 year ( inclusive ) histologically document clinically localize , adenocarcinoma prostate . 2 . Subject clinical stage T1 T2 Gleason score 6 7 ( 3+4 4+3 ) . 3 . At least one ( 1 ) MRI evaluable tumor volume 400 mm3 great . 4 . At least total 10 mm cancer tissue base MRI guide 12core biopsy . 5 . Recent ( ≤ 6 month prior study entry ) negative bone scan computerize tomography ( CT ) scan abdomen/pelvis . 6 . Life expectancy least 5 year . 7 . Subjects adequate bone marrow function define absolute peripheral granulocyte count ≥ 1,500 platelet count ≥ 100,000 , adequate hepatic function bilirubin ≤ 1.5 mg/dl serum glutamicpyruvic transaminase ( SGPT ) &lt; 4x upper limit normal , adequate renal function define serum creatinine ≤ 2.0 mg/dl 8 . Subjects must coagulation profile ( prothrombin time [ PT ] , partial thromboplastin time [ PTT ] ) 2times upper limit normal history substantial noniatrogenic bleeding diatheses . Use anticoagulant within 5days Ad5SGEREIC/Dkk3 injection limit local use ( control central line patency ) . 9 . Subject willing refrain sexual activity agree use barrier contraceptive device ( e.g . condom ) 8weeks treatment Ad5SGEREIC/Dkk3 . 10 . Subjects must sign informed consent indicate aware investigational nature study . Key Exclusion Criteria Subjects meeting follow criterion exclude : 1 . Prior primary radiation treatment prostate . 2 . Severe bladder outlet obstructive disorder ( AUA &gt; 25 ) urinary track retention . 3 . Chemotherapy , immunotherapy investigational study drug within past 4 week . 4 . Unable tolerate TRUS . 5 . Subjects uncontrolled cardiac , hepatic , renal neurologic/psychiatric disorder , opinion investigator put subject significant risk , eligible . 6 . Subjects HIV positive active hepatitis B C infection eligible . 7 . Subjects clinical history primary secondary immunodeficiency , autoimmune disease subject take immunosuppressive drug corticosteroid continuously &gt; 4 month [ &gt; 5 mg hydrocortisone/day ] ineligible . 8 . As result medical review , physical examination , Principal Investigator ( medically qualify nominee ) considers subject unfit study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>